CHMP Recommends Standard Marketing Authorisation for Janssen's COVID-19 Vaccine Jcovden

On 15 December 2022, the Committee for Human Medicinal Products (CHMP) at the European Medicines Agency (EMA) recommended that the conditional marketing authorisation for Janssen's adenovirus vector vaccine Jcovden be converted into a standard authorisation. The EU Commission followed this recommendation on 09 January 2023. A standard marketing authorisation does not need to be renewed annually. All other obligations for the pharmaceutical company remain in place.